google-site-verification: googlec7193c3de77668c9.html

Update shows sustained overall survival benefit with adjuvant osimertinib in resected EGFR-mutated lung cancer

[
An exploratory 8-year landmark update from the Phase III ADAURA trial showed that adjuvant osimertinib continued to provide a long-term overall survival benefit for patients with completely resected, EGFR-mutated stage IB–IIIA non-small cell lung cancer (NSCLC). The findings were presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).


Source link

Advertisements

See also  Chemical NDMA is much more likely to cause cancerous mutations after early-life exposure, study suggests

Check Also

Physical activity weakens link between genetic risk and depression severity, long-term data suggest

[ Major depressive disorder (MDD), one type of depression, is one of the most common …

New genetic candidates help explain why autism affects males more often than females

[ Researchers at Baylor College of Medicine, the Duncan Neurological Research Institute (Duncan NRI) at …

The medicine of the future could be driven by mechanical cell memory

[ Credit: Unsplash/CC0 Public Domain It’s not a cure for baldness. But it might eliminate …

Leave a Reply

Available for Amazon Prime